Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Melanocortin Obesity Syndrome
NCT06899178Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atomoxetine in Melanocortin obesity syndrome (MC4R), sponsored by Icahn School of Medicine at Mount Sinai. Started Sep 2026; status: recruiting.
02
Drugs
atomoxetine
03
Conditions
Melanocortin obesity syndrome (MC4R)
Beyond the preview
Go deeper on NCT06899178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899178.